C4 Therapeutics Q3 revenue beats estimates

C4 Therapeutics

06/11/2025 12:15

Overview

C4 Therapeutics Q3 revenue beats analyst expectations, adjusted EPS misses

Company raised $125 mln in equity offering, extending runway to end of 2028

Net loss for Q3 2025 increased to $32.2 mln from $24.7 mln in Q3 2024

Outlook

C4 Therapeutics expects to initiate a Phase 2 trial for cemsidomide in Q1 2026

Company plans a Phase 1b trial for cemsidomide with elranatamab in Q2 2026

C4 Therapeutics has extended its financial runway to end of 2028

Result Drivers

EQUITY OFFERING - Raised $125 mln in gross proceeds, extending financial runway to end of 2028

PFIZER COLLABORATION - Entered agreement to evaluate cemsidomide with elranatamab in relapsed/refractory MM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$11.20 mln
$6.28 mln (5 Analysts)
Q3 EPS
Miss
-$0.44
-$0.40 (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for C4 Therapeutics Inc is $10.00, about 76.3% above its November 5 closing price of $2.37

Press Release: ID:nGNX6d1yRf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)